Back to Search
Start Over
Serum IgG2 levels predict long-term protection following pneumococcal vaccination in systemic lupus erythematosus (SLE)
- Source :
- Vaccine, Vaccine, Elsevier, 2020, 38, pp.6859-6863. ⟨10.1016/j.vaccine.2020.08.065⟩, Vaccine, 2020, 38, pp.6859-6863. ⟨10.1016/j.vaccine.2020.08.065⟩
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- International audience; Systemic lupus erythematosus (SLE) patients are at risk for pneumococcal infection. Twenty-one consecutive SLE patients (40[25-75] years) received the sequential PCV13/PPSV23 vaccine and factors associated with long-term protection were analyzed. Immune protection, defined by an antigen-specific IgG concentration ≥1.3 µg/mL for at least 70% of 7 pneumococcal serotypes was assessed at baseline, 2, 6, 12 and 36 months defining long-term protection. Only 10 patients showed pneumococcal immune protection 36 months after vaccination. Eleven (52.4%) patients had no long-term protection with a seroconversion that never or only transiently occurred. SLE disease features, treatment received and immunological characteristics did not differ between protected and unprotected patients except for the pre-vaccination IgG2 serum levels. Serum IgG2 level >2.125 µg/ml showed a sensitivity of 100% and a specificity of 90.9% for long-term protection. Sequential pneumococcal vaccination conferred poor immune protection in SLE. Baseline IgG2 serum level identified patients able to benefit from pneumococcal vaccination.
- Subjects :
- Pneumococcal serotypes
Pneumococcal vaccination
[SDV]Life Sciences [q-bio]
030231 tropical medicine
Disease
Systemic erythematosus lupus
Pneumococcal Infections
Pneumococcal Vaccines
03 medical and health sciences
0302 clinical medicine
Humans
Lupus Erythematosus, Systemic
Medicine
030212 general & internal medicine
Seroconversion
Immune protection
General Veterinary
General Immunology and Microbiology
business.industry
Vaccination
IgG2
Public Health, Environmental and Occupational Health
Antibodies, Bacterial
3. Good health
[SDV] Life Sciences [q-bio]
Streptococcus pneumoniae
Infectious Diseases
Immunoglobulin G
Immunology
Molecular Medicine
business
Subjects
Details
- Language :
- English
- ISSN :
- 0264410X
- Database :
- OpenAIRE
- Journal :
- Vaccine, Vaccine, Elsevier, 2020, 38, pp.6859-6863. ⟨10.1016/j.vaccine.2020.08.065⟩, Vaccine, 2020, 38, pp.6859-6863. ⟨10.1016/j.vaccine.2020.08.065⟩
- Accession number :
- edsair.doi.dedup.....1ee3167e29bd2fec07b54da39c4228f1